Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Betamab ApS
APS
In liquidation
Advertising protection
CVR 40337326
Hørsholmvej 11, 3050
Humlebæk
Forskning og eksperimentel udvikling indenfor bioteknologi
·
NACE 721100
Est. 2019 · 7 years old
2 employees
Monitor
Share
Denmark
/
Companies
/
Forskning og eksperimentel udvikling indenfor bioteknologi
/
Betamab ApS
Overview
Financials
People & ownership
Related companies
Loading company…
People & ownership
Management
Actively employed in the business
Name
Role
Member since
Former (1)
PM
Preben Meldgaard
Unofficial title
Unofficial title
2021 – 2022
Board of directors
Non-executive oversight
Name
Role
Member since
Former (1)
TE
Teit Eliot Johansen
Chairman
Chairman
2020 – 2021
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Morten Peter Meldal
Individual
33.33–49.99%
33.33–49.99%
2020
Jan Albert Nikolaisen
Individual
10–14.99%
10–14.99%
2019
ALK-ABELLÓ A/S
Company
5–9.99%
5–9.99%
2020
Søren Mouritsen
Individual
33.33–49.99%
33.33–49.99%
2020
Jan Nikolaisen
Individual
10–14.99%
10–14.99%
2019
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
More on Betamab ApS
Overview →
Headline figures, risk assessment and company summary
Financials & key figures →
Revenue, EBITDA, balance sheet and 5-year trend
Related companies →
Corporate hierarchy, parent and subsidiary network